Bronchitis-Pipeline Review, H1 2015

Bronchitis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6641IDB
  • |
  • Pages: 45
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Bronchitis-Pipeline Review, H1 2015


Global Markets Direct's, 'Bronchitis-Pipeline Review, H1 2015', provides an overview of the Bronchitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bronchitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Bronchitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Bronchitis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Bronchitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Bronchitis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Bronchitis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Bronchitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Bronchitis Overview 6

Therapeutics Development 7

Pipeline Products for Bronchitis-Overview 7

Pipeline Products for Bronchitis-Comparative Analysis 8

Bronchitis-Therapeutics under Development by Companies 9

Bronchitis-Pipeline Products Glance 10

Clinical Stage Products 10

Early Stage Products 11

Bronchitis-Products under Development by Companies 12

Bronchitis-Companies Involved in Therapeutics Development 13

DBV Technologies S.A. 13

Hyundai Pharmaceutical Co., Ltd. 14

Mucosis B.V. 15

Myelo Therapeutics GmbH 16

PARI Pharma GmbH 17

Recipharm AB 18

Bronchitis-Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

cyclosporine liposomal-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

erdosteine-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

HOB-051-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Myelo-001-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

nitric oxide-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

respiratory syncytial virus vaccine-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

RSV vaccine-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Bronchitis-Recent Pipeline Updates 37

Bronchitis-Dormant Projects 39

Bronchitis-Discontinued Products 40

Bronchitis-Product Development Milestones 41

Featured News & Press Releases 41

Jan 23, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants 41

Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine 41

Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA 42

Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans 42

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

List of Tables

Number of Products under Development for Bronchitis, H1 2015 7

Number of Products under Development for Bronchitis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 10

Comparative Analysis by Early Stage Development, H1 2015 11

Products under Development by Companies, H1 2015 12

Bronchitis-Pipeline by DBV Technologies S.A., H1 2015 13

Bronchitis-Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2015 14

Bronchitis-Pipeline by Mucosis B.V., H1 2015 15

Bronchitis-Pipeline by Myelo Therapeutics GmbH, H1 2015 16

Bronchitis-Pipeline by PARI Pharma GmbH, H1 2015 17

Bronchitis-Pipeline by Recipharm AB, H1 2015 18

Assessment by Monotherapy Products, H1 2015 19

Number of Products by Stage and Target, H1 2015 21

Number of Products by Stage and Mechanism of Action, H1 2015 23

Number of Products by Stage and Route of Administration, H1 2015 25

Number of Products by Stage and Molecule Type, H1 2015 27

Bronchitis Therapeutics-Recent Pipeline Updates, H1 2015 37

Bronchitis-Dormant Projects, H1 2015 39

Bronchitis-Discontinued Products, H1 2015 40

List of Figures

Number of Products under Development for Bronchitis, H1 2015 7

Number of Products under Development for Bronchitis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 10

Assessment by Monotherapy Products, H1 2015 19

Number of Products by Top 10 Targets, H1 2015 20

Number of Products by Stage and Top 10 Targets, H1 2015 21

Number of Products by Top 10 Mechanism of Actions, H1 2015 22

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23

Number of Products by Top 10 Routes of Administration, H1 2015 24

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25

Number of Products by Top 10 Molecule Types, H1 2015 26

Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

DBV Technologies S.A.

Hyundai Pharmaceutical Co., Ltd.

Mucosis B.V.

Myelo Therapeutics GmbH

PARI Pharma GmbH

Recipharm AB

Bronchitis Therapeutic Products under Development, Key Players in Bronchitis Therapeutics, Bronchitis Pipeline Overview, Bronchitis Pipeline, Bronchitis Pipeline Assessment

select a license
Single User License
USD 2000 INR 143560
Site License
USD 4000 INR 287120
Corporate User License
USD 6000 INR 430680



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]